About

Tim is a tech entrepreneur from the Cambridge Cluster, passionate about using big data and AI to accelerate treatments for rare diseases. He is the Co-Founder and Chief Executive of Healx, the AI-powered, patient-inspired tech company, accelerating the discovery and development of rare disease treatments at scale. In 2019, Healx raised $56 million in Series B funding and was listed in Tech Nation’s Future Fifty cohort. In 2020, the company won 5 prizes at the CogX Awards including Grand Jury Prize and Best AI Product and was listed in CB Insights Digital Health 150.

As CEO of Healx, Tim has been listed in The Sunday Times Maserati 100 list of entrepreneurs in 2019, was was named as ‘One to watch’ in The Telegraph’s Top 50 Most Ambitious Business Leaders in 2020, and was selected as member of the Forbes Technology Council in 2022.

Tim is also the Co-Founder and Trustee of the Cambridge Rare Disease Network (CRDN). Prior to Healx and CRDN, he obtained his PhD at the University of Cambridge in the field of Biophysics and Neuroscience, developing nanobody technology for Parkinson's disease. Before moving to Cambridge UK, Tim obtained an MEng in Bio- and Chemical-Engineering from the University of Brussels.

Dr Bruce Bloom is the founder and former CEO of Cures Within Reach, a leading global non-profit saving lives by unleashing the untapped potential of human approved drugs, devices, diagnostics and nutraceuticals, testing new uses for them to quickly deliver safe and affordable treatments and cures for diseases that have no currently effective therapy.

Bruce envisioned and created CureAccelerator®, the first online redevelopment research collaboration platform, to bring together clinicians, researchers, funders, and industry to create and conduct proof of concept redevelopment clinical trials. Dr Bloom is an Ashoka Social Entrepreneur Fellow, the Patient Advisory Board Chair for the Institute for Translational Medicine, board member of the Drug Discovery Center and Chair of the Cancer Center Advancement Advisory Boards at the University of Illinois Chicago, member of the Vanderbilt Institute for Clinical and Translational Research External Advisory Board, and is on the Science Advisory Boards of Rediscovery Life Sciences, the Dr. Ralph and Marian Falk Medical Research Trust Awards Programs, the Findacure Fundamental Disease Charity, the Rare Disease Research Hub of the Westchester Biotech Project, OneThree Biotech, and Cures Within Reach for Cancer, and is a member of the editorial board of ASSAY and Drug Development Technologies.

Dr Anthony Hall graduated from King’s College London with first class joint honours in physiology and pharmacology before going on to study medicine at the Royal Free Hospital. He has over 25 years of drug development with ten years working on rare diseases.

As CMO at Healx Tony will be responsible for progressing the company’s rare disease drug candidates through the clinic. He will also oversee relationships with regulatory bodies at a global level.

Prior to joining Healx, Tony worked as CMO at Aparito and as Therapeutic Area Head of Orphan Drugs at Mereo BioPharma. He previously co-designed the development programme for DevelopAKUre, an FP7-funded project to redevelop nitisinone for the treatment of the rare metabolic disease, alkaptonuria (AKU). He is currently Trustee of Findacure and a member of the Scientific Advisory Board at the patient group charity Duchenne UK. He is also co-editor of The Patient Group Handbook for rare diseases.

Gillian Bonthron brings more than 20 years experience in financial leadership and the capital markets including fundraising, mergers and acquisitions and strategic finance in both private equity and PLC environments.Prior to joining Healx as Chief Financial Officer, Gillian held a number of senior finance positions in the biotech and support services industries including Perspectum Limited, Mitie Group PLC, Connect Group PLC and KPMG.Gillian is a member of the Institute of Chartered Accountants for Scotland and holds a first class honours degree in Accountancy and Business Law.

Mark is an experienced business development leader. As the Global Head of Business Development and Licensing, he is responsible for leading Healx's strategic and business development initiatives.

Prior to joining Healx, Mark was the Global Head of Business Development at Acrotech Biopharma where he successfully closed multiple transactions to help build the company from the start. Previously, he has also worked in Business Development at Bayer and held various positions in the pharmaceutical industry.

Mark has a Doctor of Pharmacy degree, Masters in Business Administration and post-doctoral fellowship training from Rutgers University.

Nick is a seasoned tech leader known for his expertise in building and leading highly effective and collaborative cross-disciplinary teams. Nick is responsible for the smooth daily operations of Healx, alongside leading People and Technology.

Nick has developed software products across a diverse range of industries and companies, including startups, enterprise organisations and consultancy firms. Prior to joining Healx, Nick played a key role in establishing Pivotal Labs in the UK, running the North EMEA business and leading the consulting team across Europe. At Labs Nick helped companies across many sectors to transform their software approach by applying lean agile, user centric and modern cloud methodologies.

Nick holds a Masters in Computer Science with Artificial Intelligence from Imperial College London.

Luke brings over 10 years finance experience in both start-up and corporate environments. He trained with EY at their London audit practice and then held a number of senior finance positions at pharmaceutical and biotech companies including GlaxoSmithKline Plc and Perspectum Ltd.

Luke is a member of the Institute of Chartered Accountants in England and Wales and has a first-class degree in Biochemistry, and PhD in Molecular Pharmacology.

Over the last 25 years, Richard has progressed multiple preclinical candidates and led drug discovery projects in areas of inflammatory, metabolic, CNS and rare disease.

Richard's drug discovery career began at Chiroscience, one of the UK’s first biotech companies, where he took on increasing levels of seniority as the company grew, merging with Celltech and then UCB. Following this, Richard helped build out UK based NCE (New Chemical Entity) drug discovery capabilities for Takeda. He then joined C4X Discovery, applying the company's innovative 4D molecule visualiser NMR technology to design novel NCE’s.

Richard has a strong interest in applying automation and novel technologies which shorten and improve the probability of drug discovery projects successfully reaching the clinic. At Healx he is responsible for preclinical drug discovery activities.

Richard is also a Fellow of the Royal Society of Chemistry, a Trustee of the Society of Medicines Research and has authored over 45 publications and patents.

Richard received his doctorate in Chemistry from Manchester University and undertook post doctoral studies at Arizona State University.

Miguel has over 20 years of experience in genomics, health science and biomedical research, leading the development of new methods for functional annotation of genomes and metagenomes in health and disease. For the last 10 years he has applied his expertise to the development of technological platforms to enable early drug discovery. He led the early development of the OpenTargets platform, an innovative, large-scale, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.

Miguel joined Healx in 2018, and led the development of key parts of our drug discovery technological pipeline, and is now establishing our tech strategy, roadmap and working to ensure alignment between scientific and technological teams.